Australian regulatory support for prescription medicines, from registration strategy, pathway selection and pre-submission planning through TGA evaluation and post-approval lifecycle management.
Australian registration planning is most effective when the regulatory route, dossier readiness, Australian requirements and decision points are assessed before submission timing becomes fixed. The appropriate pathway depends on the medicine, evidence package, overseas regulatory history and the proposed Australian indication.
Tricode helps sponsors establish a practical Australian position, sequence the work and identify the information that needs to be ready for an efficient registration program. This is focused prescription-medicine support; clinical-trial, OGTR and other specialist workstreams remain distinct.
The standard pathway remains central for many applications. Expedited and report-based routes require specific eligibility, documentation and timing considerations; they are not automatic alternatives to a full Australian regulatory assessment.
Plan the complete prescription-medicine registration application, including the Pre-submission Planning Form, CTD or eCTD dossier, Australian product information and response readiness.
Why It May Be Considered: Appropriate where expedited, designation or reliance criteria do not apply and a full Australian evaluation is the most suitable route.
Assess whether a Priority determination should be considered before a priority registration submission. A valid determination is required to access the pathway and does not guarantee ARTG registration.
Potential Benefit: Where eligibility requirements are met, a materially shorter targeted TGA assessment timeframe may be available while the evidentiary standard for registration remains unchanged.
Assess whether a Provisional determination and provisional registration strategy may be appropriate where the applicable criteria and evidence position can be met. A determination is not an approval outcome.
Potential Benefit: For eligible promising medicines, time-limited Australian registration may be available on preliminary clinical evidence while confirmatory evidence continues to be generated.
Evaluate whether a COR report-based route may be suitable, including the distinction between COR-A and COR-B and the Australian information that will still require attention.
Potential Benefit: Where suitable COR assessment material is available and eligibility requirements are met, the approach may reduce unnecessary duplication of evaluation and shorten the Australian assessment.
Orphan Drug Designation, Priority Review and Provisional Approval each have their own requirements, decisions and timing. They should be assessed early enough to support a credible Australian sequence, rather than treated as labels to be added late in the program.
Tricode can support the regulatory assessment, planning and preparation of the relevant Australian workstream, while keeping the sponsor’s clinical, evidence and commercial assumptions visible in the decision-making process.
Potential Benefit: For an eligible orphan medicine, a valid designation can provide practical regulatory benefits, including waiver of relevant TGA application and evaluation fees for the associated registration application while the designation remains valid and the application remains within scope.
Important distinction: designation or determination may support access to a particular process, but it does not itself result in registration on the Australian Register of Therapeutic Goods (ARTG).
Overseas approvals and assessment reports can be relevant to Australian planning, but their practical value depends on the particular medicine, the overseas decision, the available reports and TGA requirements. Full overseas approval alone does not establish COR eligibility.
Tricode can help sponsors assess the potential relevance of COR-A, COR-B, Project Orbis or other collaborative approaches where they are available and appropriate, and integrate that analysis with the Australian submission plan.
A biosimilar workstream illustrates how a mature global dossier must still be assessed against Australian requirements.
Review the proposed indication, overseas approvals, comparability evidence, manufacturing position and global assessment history.
Confirm the Australian reference product, evaluate bridging considerations and identify Australian-specific dossier, Module 1, PI, CMI and other content gaps.
Establish the submission strategy, coordinate technical input, support TGA evaluation and response management, and plan post-approval lifecycle requirements.
Outcome sought: a clear Australian registration strategy, understood reference-product and bridging requirements, and defined ownership from planning through evaluation and lifecycle.
A well-managed submission requires more than assembling a dossier. Tricode supports practical planning across the Australian application type, CTD or eCTD sequence, product-specific documents, Product Information, Consumer Medicine Information, Risk Management Plan where required, evidence readiness and defined sponsor responsibilities.
During evaluation, sponsors need a clear process for interpreting requests, coordinating subject-matter input and maintaining decision discipline. Tricode can support regulatory interaction, question management and response coordination, including planning around information requests made under section 31 where relevant.
The agreed scope is tailored to the program and can sit alongside internal regulatory teams and specialist technical contributors.
Registration is not the end of the Australian regulatory workstream. Changes to a medicine, its manufacturing, indication, product information, safety position or supply arrangements may require a structured assessment of the appropriate Australian lifecycle action.
Tricode supports lifecycle planning and defined regulatory activities including variations, notifications, renewal considerations, product-information support and ongoing Australian regulatory advice.
Registration strategy can affect downstream PBAC/PBS planning, and regulatory sequencing should therefore be considered in the context of broader market-access and commercial planning.
Tricode considers this interface as part of the registration plan and can work alongside appropriately qualified market-access advisers. Specialist HTA, health-economic modelling, pricing and reimbursement activities can remain with those advisers.
For the broader Australian picture, read Tricode’s guide to the relationship between TGA registration, clinical development, market access and reimbursement planning, and wider commercial considerations.
Read the Strategic Guide →Engagements are structured around the actual Australian regulatory gap, with clear ownership of the agreed workstream.
Review the medicine, evidence, intended indication, overseas history and Australian objectives.
Establish the pathway, timing, dependencies and decision points for the program.
Coordinate submission readiness, Australian content and the defined regulatory workstream.
Support TGA interaction, changes and post-approval requirements within scope.
Australian-specific support across registration strategy, TGA evaluation and lifecycle requirements.
Global evidence and regulatory history are assessed against Australian pathway and dossier requirements.
Registration choices are considered alongside development, evidence, market-entry and lifecycle implications.
Tricode can manage or lead a defined Australian regulatory workstream or work alongside the sponsor’s regulatory team.
Regulatory information on this page was reviewed on 7 October 2026. Requirements should be confirmed for the specific medicine and program before implementation.
Discuss registration strategy, pathway selection, submission planning, TGA evaluation support or a defined Australian lifecycle workstream.
Discuss Your Australian Registration Strategy